New assay may boost targeted treatment of non-hodgkin lymphoma

(Elsevier) Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40 percent of cases). Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype. In a report in The Journal of Molecular Diagnostics, researchers describe their development of a reliable, accessible, rapid, and cost-effective new gene expression signature assay that can enhance lymphoma management by helping to match tumors with the appropriate targeted therapy.

Original Article: New assay may boost targeted treatment of non-hodgkin lymphoma

More From BioPortfolio on "New assay may boost targeted treatment of non-hodgkin lymphoma"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications